GlassScriptPhysician profile
Devin R Southworth
NPI 1689244022
$5,395.29
in general payments reported to CMS, 2019-2025
27 companies · $987 in 2025
The $987 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $1,336 · 2023: $1,238 · 2024: $1,444 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.07 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $531.55 | 2022-2025 | Qelbree |
| Lundbeck LLC | $496.76 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $355.03 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $327.45 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $321.12 | 2021-2025 | Caplyta |
| Corium, LLC | $319.93 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $275.93 | 2022-2024 | Spravato |
| Alkermes, INC. | $233.88 | 2021-2024 | Lybalvi, Aristada |
| Tris Pharma INC | $221.10 | 2021-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $201.92 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $100.22 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $99.19 | 2022-2025 | Aplenzin |
| Vertical Pharmaceuticals, LLC | $95.57 | 2024-2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $91.49 | 2021-2024 | Austedo Xr, Austedo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $76.01 | 2022-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $67.43 | 2022-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $65.38 | 2023-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $59.31 | 2022 | |
| Braeburn INC. | $49.10 | 2025 | Brixadi |
| Eisai INC. | $40.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $38.98 | 2021-2022 | |
| Biogen, INC. | $29.07 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $27.90 | 2022-2023 | Trintellix |
| Noven Therapeutics, LLC | $17.27 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $16.37 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Southworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.